Renaissance Technologies
VKTX icon

Renaissance Technologies’s Viking Therapeutics VKTX Stock Holding History

Renaissance Technologies’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-32,700
Closed -$867K – 3972
2025
Q2 		$867K Sell
32,700
-295,000
-90% -$7.77M ﹤0.01% 2581
2025
Q1 		$7.91M Buy
+327,700
New +$10.4M 0.01% 1137
2024
Q4 		– Sell
-184,100
Closed -$11.7M – 3939
2024
Q3 		$11.7M Buy
184,100
+24,700
+15% +$1.45M 0.02% 964
2024
Q2 		$8.45M Buy
+159,400
New +$10.4M 0.01% 1018
2023
Q3 		– Sell
-57,000
Closed -$924K – 4144
2023
Q2 		$924K Sell
57,000
-704,200
-93% -$14.8M ﹤0.01% 2513
2023
Q1 		$12.7M Sell
761,200
-189,400
-20% -$1.96M 0.02% 964
2022
Q4 		$8.94M Sell
950,600
-95,800
-9% -$428K 0.01% 1152
2022
Q3 		$2.85M Buy
1,046,400
+180,200
+21% +$590K ﹤0.01% 1793
2022
Q2 		$2.5M Sell
866,200
-101,149
-10% -$250K ﹤0.01% 2026
2022
Q1 		$2.9M Buy
967,349
+724,476
+298% +$2.6M ﹤0.01% 1948
2021
Q4 		$1.12M Buy
+242,873
New +$1.36M ﹤0.01% 2562
2021
Q1 		– Sell
-179,000
Closed -$1.01M – 3738
2020
Q4 		$1.01M Buy
179,000
+141,900
+382% +$860K ﹤0.01% 2490
2020
Q3 		$216K Buy
+37,100
New +$255K ﹤0.01% 3082
2018
Q2 		– Sell
-832,500
Closed -$3.64M – 3548
2018
Q1 		$3.64M Sell
832,500
-70,800
-8% -$392K ﹤0.01% 2020
2017
Q4 		$3.67M Buy
903,300
+500,700
+124% +$1.45M ﹤0.01% 1994
2017
Q3 		$769K Buy
402,600
+103,600
+35% +$118K ﹤0.01% 2667
2017
Q2 		$323K Buy
299,000
+33,200
+12% +$42.2K ﹤0.01% 2882
2017
Q1 		$388K Buy
265,800
+102,600
+63% +$143K ﹤0.01% 2845
2016
Q4 		$194K Buy
163,200
+141,900
+666% +$160K ﹤0.01% 3012
2016
Q3 		$30K Buy
+21,300
New +$28.2K ﹤0.01% 3278

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies's VKTX Position: Q3 2025 in Review

Renaissance Technologies sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 32,700 shares — an estimated $867K sold.

Renaissance Technologies first reported a position in VKTX in Q3 2016 and held it in 20 quarters. The position peaked at $12.7M in Q1 2023. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Renaissance Technologies reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Renaissance Technologies sold 32,700 Viking Therapeutics shares in Q3 2025, an estimated $867K.
  • Renaissance Technologies first reported a position in Viking Therapeutics in Q3 2016 and held it in 20 quarters.
  • Renaissance Technologies's Viking Therapeutics position peaked at $12.7M in Q1 2023.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.